Anebulo Pharmaceuticals, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Richard Anthony Cunningham
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1415 Ranch Road 620 South Lakeway TX United States of America 78734
- IPO Date
- May 7, 2021
- CIK
- 0001815974
- Website
- anebulo.com
- Similar Companies
- Business
- Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) is a clinical-stage biotechnology company focused on developing novel treatments for central nervous system (CNS) disorders, including addiction and substance use disorders. The company advances a pipeline of product candidates targeting unmet medical needs in areas such as opioid use disorder, alcohol use disorder, and other CNS conditions; its lead candidate, ANEB-001, is an oral formulation of sodium oxybate designed to reduce cravings and withdrawal symptoms in patients with opioid addiction, currently in Phase 1 clinical development; additional preclinical programs explore GABAergic mechanisms for broader addiction therapies. Anebulo operates primarily in the United States, with clinical trials conducted through contract research organizations across North America, and targets healthcare providers, addiction treatment centers, and patients seeking non-opioid alternatives in the behavioral health sector. Founded in 2019 and headquartered in Austin, Texas, the company maintains a lean structure with no noted subsidiaries or parent entities. In recent developments, Anebulo completed an upsized initial public offering in November 2023, raising approximately $13.2 million to fund ANEB-001's advancement into Phase 1 trials, which dosing commenced in early 2024 with topline data expected in late 2024 or early 2025; the company also expanded its leadership team in 2024 with key hires in clinical development and regulatory affairs to support pipeline progression.
Anebulo Pharmaceuticals (NASDAQ:ANEB) & Replimune Group (NASDAQ:REPL) Critical Comparison
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates
Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC
Anebulo Pharmaceuticals (NASDAQ:ANEB) Trading Down 13.6% – What’s Next?
Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Price Down 13.6% – What’s Next?
Anebulo Pharmaceuticals Announces Final Results of Tender Offer
Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer
Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates
Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity
Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
Galehead Development to Collaborate With Rivian Automotive on Renewable Energy Project Development
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates